Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.42 | -1.39% | -0.02 |
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -1.39% | |
| Wide Bands | Range Expansion | -1.39% | |
| Oversold Stochastic | Weakness | -1.39% | |
| Lower Bollinger Band Walk | Weakness | -1.05% | |
| Inside Day | Range Contraction | -1.05% | |
| Wide Bands | Range Expansion | -1.05% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 18 hours ago |
| Reversed from Up | about 18 hours ago |
| Gapped Up (Full) | about 18 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
| Up 3% | about 18 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2024
Checkpoint Therapeutics, Inc. Description
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Immune Checkpoint Solid Tumor Cancers Checkpoint Inhibitor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical Tumor Necrosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.62 |
| 52 Week Low | 1.3 |
| Average Volume | 392,847 |
| 200-Day Moving Average | 2.10 |
| 50-Day Moving Average | 1.91 |
| 20-Day Moving Average | 1.73 |
| 10-Day Moving Average | 1.57 |
| Average True Range | 0.11 |
| RSI (14) | 21.88 |
| ADX | 30.82 |
| +DI | 8.28 |
| -DI | 25.06 |
| Chandelier Exit (Long, 3 ATRs) | 1.81 |
| Chandelier Exit (Short, 3 ATRs) | 1.75 |
| Upper Bollinger Bands | 2.12 |
| Lower Bollinger Band | 1.34 |
| Percent B (%b) | 0.11 |
| BandWidth | 45.22 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.11 |
| MACD Histogram | -0.0333 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.56 | ||||
| Resistance 3 (R3) | 1.57 | 1.53 | 1.53 | ||
| Resistance 2 (R2) | 1.53 | 1.50 | 1.53 | 1.52 | |
| Resistance 1 (R1) | 1.48 | 1.48 | 1.46 | 1.47 | 1.52 |
| Pivot Point | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 |
| Support 1 (S1) | 1.39 | 1.41 | 1.37 | 1.38 | 1.32 |
| Support 2 (S2) | 1.35 | 1.39 | 1.35 | 1.32 | |
| Support 3 (S3) | 1.30 | 1.35 | 1.31 | ||
| Support 4 (S4) | 1.29 |
